Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study.
Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study.
复制标题
重组人促红细胞生成素成功治疗与活动性全身性幼年类风湿性关节炎相关的严重贫血:一项试点研究。
DOI:
10.1002/art.1780350622
复制
发表时间:
1992
影响因子:
--
通讯作者:
E. Cirla
中科院分区:
文献类型:
--
作者:
F. Fantini;M. Gattinara;V. Gerloni;P. Bergomi;E. Cirla
We have previously reported an association be1 ween the presence of anti-topoisomerase I and cancer in patients with scleroderma (1). We are currently providing followup care for 148 patients who meet the American College of Rheumatology (formerly, the American Rheumatism Association) criteria for the classification of scleroderma (2). Thus far, 7 of 36 anti-topoisomerase I-positive scleroderma patients have had cancer, compared with 2 of 112 negative for anti-topoisomerase I (2= 11.94, P= 0.0005, odds ratio 13.27, at 95% confidence limits 2.33-57.5). The antibody was present in all of these patients prior to the diagnosis of cancer.Of the 7 anti-topoisomerase I-positive scleroderma patients with cancer, 4 had lung cancer, 1 had colon cancer, 1 had lymphocytic lymphoma, and 1 had metastatic brain cancer, with the primary site unknown. Three were men and 4 were women; their ages ranged from 33 to 61 (mean 50). Of the 2 scleroderma patients without anti-topoisomerase I who developed cancer, 1 patient had ovarian carcinoma 1 year prior to the diagnosis of scleroderma and the other tleveloped oral cancer 10 years after a diagnosis of CKEST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias). Both patients were women; their ages were 62 and 57 at the time of the study.